Loading exclusive…
$CLBT: Masked by Revenue Miss and Soft Q3 Outlook
Cellebrite beats on EPS but misses on revenue; Q3 guidance signals slowing momentum in digital intelligence.
Key Points
- Q2 EPS of $0.11 beat consensus of $0.09.
- Revenue missed estimates, indicating top-line weakness.
- Q3 guidance was soft, signaling continued demand headwinds.
- Stock dropped ~5% post-print as investors focused on revenue miss and weak outlook.
What To Watch
- Q3 revenue guidance updates and any changes in procurement cycles.
- Management commentary on competitive landscape and new product adoption.
- Q4 earnings setup for potential revenue stabilization signals.